You have 9 free searches left this month | to do more
Showing 1 - 25 of
615 items
Trials Per Page
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
Z
PD1 Integrated Anti-PSMA CART in Treating Patients With Castrate-Resistant Prostate Cancer
Recruiting
  • Castrate-Resistant Prostate Cancer
  • PD1-PSMA-CART cells
  • Hangzhou, Zhejiang, China
    The First Affiliated Hospital, Zhejiang University
2022-02-26
Feb 26, 2022
F
Microbiota Transplant in Advanced Lung Cancer Treated With Immunotherapy
Recruiting
  • Lung Cancer
  • Microbiota Transplant plus anti PD1 therapy
  • anti PD1 therapy
  • Madrid, Spain
    Hospital Universitario Ramón y Cajal
2021-11-16
Nov 16, 2021
U
Study of PD1 Blockade by Pembrolizumab With Stereotactic Body Radiotherapy in Advanced Solid Tumors
Active, not recruiting
  • Solid Tumor
  • Chicago, Illinois
    University of Chicago
2022-03-14
Mar 14, 2022
B
PD1 Antibody and Lenalidomide as a Treatment for EBV-HLH or CAEBV
Recruiting
  • EBV Infection
  • Beijing, Beijing, China
    Beijing Friendship Hospital, Capital Medical University
2022-01-04
Jan 4, 2022
U
Intrathecal Application of PD1 Antibody in Metastatic Solid Tumors With Leptomeningeal Disease (IT-PD1/ NOA 26)
Recruiting
  • Leptomeningeal Disease
  • Nivolumab [Opdivo]
  • Freiburg, Germany
  • +4 more
2021-12-13
Dec 13, 2021
C
Interest of Anti-telomerase T CD4 Immune Responses for Predicting the Effectiveness of Immunotherapies Targeting PD1 / PDL1
Recruiting
  • Cancer
  • Biological samples
  • Anti PD1/PDL1 treatment
  • Besancon, France
    University Hospital of Besançon
2021-07-30
Jul 30, 2021
C
64Cu-DOTA-pembrolizumab PET for the Study of PD1 Expression
Not yet recruiting
  • Hematopoietic and Lymphoid Cell Neoplasm
  • Malignant Solid Neoplasm
  • Copper Cu 64-DOTA-pembrolizumab
  • +2 more
  • Duarte, California
    City of Hope Medical Center
2022-02-16
Feb 16, 2022
S
PD1 Antibody Toripalimab and Chemoradiotherapy for dMMR/MSI-H Locally Advanced Colorectal Cancer
Recruiting
  • DMMR Colorectal Cancer
  • +2 more
  • PD-1 Antibody
  • +4 more
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
2021-09-22
Sep 22, 2021
S
Phase II-III Clinical Trial of PD1 Antibody (Toripalimab), Lenvatinib and GEMOX Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors
Recruiting
  • Intrahepatic Cholangiocarcinoma
  • +3 more
  • Neoadjuvant treatment
  • Shanghai, Shanghai, China
    Zhongshan hospital
2021-07-05
Jul 5, 2021
A
Effect of Tramadol Versus Morphine on PD1 and PD1-ligand in Patients With Chronic Cancer Pain
Recruiting
  • Chronic Pain
  • Tramadol Hydrochloride
  • Assiut, Egypt
    Assiut University
2021-01-13
Jan 13, 2021
S
Engineered TILs/CAR-TILs to Treat Advanced Solid Tumors
Recruiting
  • Liver Cancer
  • +7 more
  • TILs and CAR-TILs targeting HER2, Mesothelin, PSCA, MUC1, Lewis-Y, GPC3, AXL, EGFR, Claudin18.2/6, ROR1, GD1, or B7-H3
  • Guangzhou, China
    Second Affiliated Hospital of Guangzhou Medical University
2021-04-09
Apr 9, 2021
C
Tumor Associated Antigen Specific T Cells (TAA-T) With PD1 Inhibitor for Lymphoma
Recruiting
  • Hodgkin Lymphoma
  • Diffuse Large B Cell Lymphoma
  • Salt Lake City, Utah
  • +1 more
2021-07-14
Jul 14, 2021
S
Combined Therapy Using Oxaliplatin and Gemcitabine Chemotherapy, Lenvatinib and PD1 Antibody (JS001) for Patients With Advanced and Unresectable Intrahepatic Cholangiocarcinoma
Active, not recruiting
  • Cholangiocarcinoma, Intrahepatic
  • combined therapy using oxaliplatin and gemcitabine chemotherapy, Lenvatinib and PD1 antibody (JS001)
  • Shanghai, Shanghai, China
    Zhongshan Hospital
2021-07-05
Jul 5, 2021
T
A Pilot Study of Sequential ONCOS-102, an Engineered Oncolytic Adenovirus Expressing GMCSF, and Pembrolizumab in Patients With Advanced or Unresectable Melanoma Progressing After Programmed Cell Death Protein 1 (PD1) Blockade - 2020
Completed
Has Results
  • Advanced or Unresectable Melanoma Progressing After PD1 Blockade
  • ONCOS-102
  • +2 more
  • Baltimore, Maryland
  • +3 more
2021-10-11
Oct 11, 2021
W
A Phase II Study to Test the Efficacy of AB928 (Dual Adenosine Receptor Antagonist) and AB122 (a PD1 Checkpoint Inhibitor) in Combination With Short Course Radiotherapy and Consolidation Chemotherapy for Rectal Cancer.
Not yet recruiting
  • Rectal Cancer
  • Etrumadenant (AB928)
  • +3 more
  • New York, New York
  • +2 more
2022-03-02
Mar 2, 2022
S
CD19 CAR-T Expressing IL7 and CCL19 Combined With PD1 mAb for Relapsed or Refractory Diffuse Large B Cell Lymphoma
Recruiting
  • Diffuse Large B-cell Lymphoma
  • CD19-7×19 CAR-T plus PD1 monoclonal antibody
  • Hangzhou, Zhejiang, China
    2nd Affiliated Hospital, School of Medicine, Zhejiang University
2020-06-26
Jun 26, 2020
S
Combined PD1 Inhibitor and Decitabine in Elderly Patients With Relapse and Refractory Acute Myeloid Leukemia
Not yet recruiting
  • Acute Myeloid Leukemia
  • (no location specified)
2020-04-16
Apr 16, 2020
M
A Study of Concurrent Chemoradiation in Combination With or Without PD1 Inhibitor AB122 Adenosine 2a Receptor / Adenosine 2b Receptor Inhibitor AB928 Therapies in Locally Advanced Head and Neck Cancers
Not yet recruiting
  • Head and Neck Cancer
  • +9 more
  • Nashville, Tennessee
    Vanderbilt-Ingram Cancer Center
2022-04-06
Apr 6, 2022
S
Comparison of PD1+T Cell Expression in Peripheral Blood for Cardiac Function Prognosis in Patients With Acute MI
Recruiting
  • PD1
  • Acute Myocardial Infarction
  • PD1+ T Cell Expression
  • Hangzhou, Zhejiang, China
    The Second Affiliated Hospital of Zhejiang University, School of
2022-02-22
Feb 22, 2022
Z
Anlotinib in Combination With PD1 With Gemcitabine Plus(+)Cisplatin for Unresectable or Metastatic Biliary Tract Cancer
Unknown status
  • Biliary Tract Cancer
  • Anlotinib Hydrochloride in Combination With PD1 With Gemcitabine Plus(+)Cisplatin
  • Gemcitabine Plus(+)Cisplatin
  • Hangzhou, Zhejiang, China
    Zhejiang Cancer Hospital
2020-03-06
Mar 6, 2020
S
Anti-PD1 Antibody Toripalimab Combined With Gemox as First-line Therapy in Late-stage Intrahepatic Cholangiocarcinoma
Recruiting
  • Intrahepatic Cholangiocarcinoma
  • Gemox combimed PD1 antibody
  • Shanghai, Shanghai, China
    Zhongshan hospital
2021-07-07
Jul 7, 2021
A
Assessing the Tolerance and Clinical Benefit of feCAl tranSplantation in patientS With melanOma
Recruiting
  • Melanoma
  • Nantes, France
  • +2 more
2022-03-28
Mar 28, 2022
S
PD1 Antibody (Toripalimab), GEMOX and Lenvatinib Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors
Recruiting
  • Cholangiocarcinoma, Intrahepatic
  • neoadjuvant treatment
  • Shanghai, Shanghai, China
    Zhongshan hospital
2020-08-07
Aug 7, 2020
M
Methylphenidate and Physical Activity to Reduce Cancer Related Fatigue Due to Anti PD1 Immunotherapy
Active, not recruiting
  • Advanced Malignant Neoplasm
  • +2 more
  • Laboratory Biomarker Analysis
  • +5 more
  • Houston, Texas
    M D Anderson Cancer Center
2021-11-09
Nov 9, 2021
N
A Study to Evaluate the Combination of Nivolumab With ADG106 in Metastatic NSCLC
Recruiting
  • Metastatic Non Small Cell Lung Cancer
  • Singapore, Singapore
  • +1 more
2022-03-10
Mar 10, 2022